| First Author | Ayroldi E | Year | 1999 |
| Journal | Blood | Volume | 94 |
| Issue | 10 | Pages | 3456-67 |
| PubMed ID | 10552956 | Mgi Jnum | J:58362 |
| Mgi Id | MGI:1347408 | Doi | 10.1182/blood.v94.10.3456.422k33_3456_3467 |
| Citation | Ayroldi E, et al. (1999) Cloning and expression of a short Fas ligand: A new alternatively spliced product of the mouse Fas ligand gene. Blood 94(10):3456-67 |
| abstractText | The Fas/FasL system mediates apoptosis in several different cell types, including T lymphocytes. Fas ligand (FasL), a 40-kD type II membrane protein also expressed in activated T cells, belongs to the tumor necrosis factor ligand family. We describe a new alternative splicing of mouse FasL, named FasL short (FasLs), cloned by reverse transcriptase-polymerase chain reaction. FasLs is encoded by part of exon 1 and part of exon 4 of FasL gene. The protein encoded by FasLs mRNA has a putative initiation code at position 756 and preserves the same reading frame as FasL, resulting in a short molecule lacking the intracellular, the transmembrane, and part of the extracellular domains. RNase protection and immunoprecipitation analysis showed that FasLs is expressed in nonactivated normal spleen cells and in hybridoma T cells and that it is upregulated upon activation by anti-CD3 monoclonal antibody (MoAb). Moreover, FasLs-transfected cells expressed soluble FasLs in the supernatant and became resistant to apoptosis induced by agonist anti-Fas MoAb. Thus, FasLs, a new alternative splicing of FasL, is involved in the regulation of Fas/FasL-mediated cell death. |
